AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04355026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
Description: bromhexine 16 mg TID hydroxychloroquine 200 mg BID
Study NCT04355026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
Description: bromhexine 16 mg TID hydroxychloroquine 200 mg BID
Study NCT02157103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 25 mg in 1 ml subcutaneously daily
Description: Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
Study NCT03000686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
Study NCT03584984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable gelatin sponge
Description: Filling the socket with an absorbable gelatin sponge foam pack
Study NCT02958423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial DCS Healthy Volunteers
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
Study NCT02958423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal DCS Healthy Volunteers
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
Study NCT02958423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial DCS CPP patients
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
Study NCT02958423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal DCS CPP patients
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
Study NCT03000686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
Study NCT01785108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg
Study NCT03468335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent.
Study NCT02796118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral
Study NCT01785108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg X 2
Study NCT01785108 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg X 2
Study NCT02796118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03705130 — intervention group
Intervention type: DEVICE
Intervention: Single Vision Contact Lens
Description: Spherical Contact Lens worn on non-dispensing basis
Study NCT03705130 — intervention group
Intervention type: DEVICE
Intervention: Multifocal Contact Lens 1
Description: Multifocal Contact Lens worn on non-dispensing basis
Study NCT03705130 — intervention group
Intervention type: DEVICE
Intervention: Multifocal Contact Lens 2
Description: Multifocal Contact Lens worn on non-dispensing basis
Study NCT02825641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study NCT02825641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study NCT02825641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study NCT02825641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study NCT05376436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise challenge test (ECT)
Description: Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
Study NCT02878941 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Synovial Fluid Analysis
Description: Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
Study NCT05107141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation
Description: Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
Study NCT05107141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bone graft plus a collagen membrane
Study NCT01700036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1-Antitrypsin (AAT)
Description: AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
Study NCT01428050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% NaCl Solution
Description: 1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
Study NCT01428050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers Solution
Description: 15cc/kg/hr for intraoperative fluids
Study NCT03802955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
Study NCT01176708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipeptidyl peptidase 4 (DPP4) inhibitor
Description: One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 2.
Study NCT01627626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute.
Study NCT01676558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01627626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0.9% saline solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose A
Description: ITI-214 Dose A Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose B
Description: ITI-214 Oral Solution Dose B
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose C
Description: ITI-214 Dose C Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose D (Elderly)
Description: ITI-214 Dose D (Elderly) Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ITI-214 Matching Placebo Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose E
Description: ITI-214 Dose E Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose F
Description: ITI-214 Dose F Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose G
Description: ITI-214 Dose G Oral Solution
Study NCT01900522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose H
Description: ITI-214 Dose H Oral Solution
Study NCT00691457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free contact lens solution
Description: Solution
Study NCT00691457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Multiplus contact lens solution
Description: Solution
Study NCT00691457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care contact lens solution
Description: Solution
Study NCT01785108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT00922246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)
Description: The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
Study NCT00334737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa Injection
Description: darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
Study NCT00334737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin alfa injection
Description: Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
Study NCT00334737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham injection
Description: sham injection other names: not applicable
Study NCT03559517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
Study NCT03559517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
Study NCT03915990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: umbilical and middle cerebral artery Doppler
Description: Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
Study NCT03915990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: umbilical and middle cerebral artery Doppler
Description: Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
Study NCT04105192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 84 days, plecebo or experimental product
Study NCT04105192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 84 days, plecebo or experimental product
Study NCT04119752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin powder
Description: 10g of curcumin powder
Study NCT04119752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g of sucralose
Study NCT04114916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apigenin, luteonin, grapefruit extract and citrolive
Description: Two capsules daily at breakfast and dinner.
Study NCT04114916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrina
Description: Two capsules daily at breakfast and dinner.
Study NCT02018484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Replacement
Study NCT01084577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag
Description: AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
Study NCT01084577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul® Silver
Description: Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
Study NCT01101672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic colectomy
Description: Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
Study NCT01101672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic colectomy
Description: Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
Study NCT00288015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
Study NCT02386462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
Study NCT02386462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT01873326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT01602640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Description: Conventional dose
Study NCT01602640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Midazolam infusion
Description: Conventional dose
Study NCT05374889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain Proprioception Exercises
Description: basketball-specific target shooting in open kinetic chain
Study NCT03898024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Study NCT03898024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Study NCT04244500 — intervention group
Intervention type: PROCEDURE
Intervention: swab sampling
Description: Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
Study NCT02379819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 Implant
Study NCT02200094 — intervention group
Intervention type: DRUG
Intervention: Low dose of Telmisartan, once daily
Study NCT02200094 — intervention group
Intervention type: DRUG
Intervention: High dose of Telmisartan, once daily
Study NCT01839331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL Injection of Ampion
Study NCT01839331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mL Injection of Ampion
Description: 10 mL Injection of Ampion
Study NCT01839331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study NCT01042067 — intervention group
Intervention type: OTHER
Intervention: Blood specimens (whole blood, serum, plasma)
Description: The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
Study NCT02845986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
Study NCT02845986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
Study NCT00924677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency neurotomy for genicular nerve
Description: RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
Study NCT00924677 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: radiofrequency neurotomy sham therapy
Description: The placebo (sham) group received the same procedure without activation of the RF generator.
Study NCT03798639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT03798639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03798639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03798639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy
Study NCT02457650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
Study NCT02457650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
Study NCT01839331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mL Injection of Placebo
Description: 10 mL Injection of Placebo
Study NCT03649243 — intervention group
Intervention type: DRUG
Intervention: Propolis spray
Description: Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
Study NCT03224390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital family planning screening and referral service
Description: Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
Study NCT00703820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: See Detailed Description